(TrkB), they are tyrosine-phosphorylated in response to neurotrophin stimulation, and they enhance the activation of mitogen-activated protein kinase in Trk-expressing cells. Moreover, neurotrophin treatment of primary cortical neurons stimulates ShcB/ShcC-Trk interaction and the tyrosine phosphorylation of ShcB/ShcC, indicating that they are bona fide targets of the Trk receptors in vivo. Interestingly, two proteins (pp60 and pp75) coimmunoprecipitate with ShcB and ShcC in response to neurotrophin stimulation in primary cortical neurons, suggesting a potential role of these unknown targets in neurotrophin signaling. Collectively, these results demonstrate that ShcB and ShcC, and their co-immunoprecipitating proteins, are activated by the Trk receptors in primary neurons.
(TrkB), they are tyrosine-phosphorylated in response to neurotrophin stimulation, and they enhance the activation of mitogen-activated protein kinase in Trk-expressing cells. Moreover, neurotrophin treatment of primary cortical neurons stimulates ShcB/ShcC-Trk interaction and the tyrosine phosphorylation of ShcB/ShcC, indicating that they are bona fide targets of the Trk receptors in vivo. Interestingly, two proteins (pp60 and pp75) coimmunoprecipitate with ShcB and ShcC in response to neurotrophin stimulation in primary cortical neurons, suggesting a potential role of these unknown targets in neurotrophin signaling. Collectively, these results demonstrate that ShcB and ShcC, and their co-immunoprecipitating proteins, are activated by the Trk receptors in primary neurons.
Nerve growth factor (NGF), 1 a representative of the neurotrophin family of growth factors, plays a critical role in the differentiation, proliferation, survival, and cell death of neurons and neural tumors (2) (3) (4) (5) . Neurotrophins act on two types of cell surface receptors: high affinity tyrosine kinase Trk receptors (including TrkA, TrkB, and TrkC) and the low affinity neurotrophin receptor p75 NTR . Trk receptors play a crucial role in neuronal survival and differentiation, whereas p75 NTR facilitates ligand binding to the Trk receptors and is a regulator of cell death (3) . TrkA is a receptor for NGF and neurotrophin-6 (NT-6); TrkB is a receptor for BDNF and NT4/5; TrkC is the primary receptor for NT-3 (6) . No interactions between NGF and TrkB or BDNF/NT-4/5 and TrkA are observed. The p75 NTR binds all known neurotrophins with similar equilibrium binding kinetics (7) .
Through Trk receptors, neurotrophins stimulate a variety of cellular responses including survival, differentiation, proliferation, and apoptosis, in different cell types, by pathways that involve the activation of Ras, Rap1, Raf, MAPK/extracellular signal-regulated kinase, phospholipase C-␥1 (PLC-␥1), Src, CHK, and phosphatidylinositol 3-kinase (PI 3-kinase). Although PLC-␥1 and CHK directly bind to the Trk receptors, the other pathways are activated through signaling adapters such as Shc (8, 9) , Grb2 (10), Gab1 (11) , rAPS, SH2-B (12) , and FRS2 (10, 13 (14, 15) . Trk receptors phosphorylate and activate signaling proteins through the recruitment of proteins to these tyrosine residues in an active receptor complex. As shown in Fig.  2A, FRS2 and ShcA directly bind to rat TrkA at Tyr 499 (13) whereas the site of PLC-␥1 and CHK binding to TrkA is Tyr 794 (10) . Interestingly, Grb2, in addition to being indirectly recruited to Trk via multiple adapters such as Shc and FRS2, also directly binds to the activation loop tyrosine residues, Tyr 683 and Tyr 684 , on TrkA (10) . Receptors mutated at individual phosphotyrosine, Tyr(P), sites required for coupling Trk to specific signal transduction pathways have been a useful tool to correlate changes in biological responses to specific changes in Trk receptor protein: protein interactions. For example, it has recently been reported that mutation of Tyr 515 on TrkB, the shared Tyr(P) residue involved in recruiting both Shc and FRS2 to the Trk receptors (13) , is essential for sympathetic neuronal survival and local axon growth (16) .
In an effort to isolate new signaling molecules utilized by the neurotrophic Trk receptors, we have performed several yeast two-hybrid screens using the ICD of TrkA, TrkB, and TrkC as baits. As a result, we isolated a cDNA encoding human ShcB (also called Sck or Sli), a member of the Shc adaptor family including ShcA, ShcB, and ShcC (also called N-Shc). ShcB is highly expressed in both the peripheral and central nervous systems (8, 9, 17) . This is of particular relevance because ShcA is weakly expressed in sympathetic neurons, and not at all in sensory neurons in the peripheral nervous system (1, 18) . By comparison, ShcC is highly expressed in the central nervous system as well as in the sympathetic and neural crest-derived, dorsal root ganglia sensory neurons in the peripheral nervous system (1, 18) . Interestingly, ShcA is expressed maximally in neuronal stem cells in the brain but is lost in post-mitotic neurons. In contrast, ShcC is not present in neural stem cells but is increasingly expressed during post-natal development (9) , suggesting that ShcA and ShcC may support different roles in the proliferation and differentiation of neurons.
There are three isoforms of ShcA (p46, p52, and p66), one isoform of ShcB (p68), and two isoforms of ShcC (p55 and p69) generated through differential splicing or translation initiation codons (17) . All Shc isoforms contain a C-terminal Src homology 2 (SH2) domain, a central proline-rich region (CH1), and an N-terminal phosphotyrosine binding (PTB) domain (19) . The N-terminal extension of the longer isoforms (also contained within the single ShcB gene) encodes a second proline-rich collagen homology region (CH2). ShcA, ShcB, and ShcC share high sequence identity in their PTB and SH2 domains (over 70% identical in amino acid sequence) but in the CH1 and CH2 regions, the sequence identity is less than 35% (1, 17, 18, 20) . Binding of the ShcA PTB domain to target sites is affected by residues N-terminal to the Tyr(P) residue, whereas SH2 domain binding is modulated by amino acids C-terminal to the Tyr(P) residue (8) . These results indicate that the two domains utilize different recognition sequences to regulate protein-protein interactions and suggest that the Shc proteins bridge together different tyrosine-phosphorylated intracellular proteins. Moreover, phosphorylated ShcA activates the Ras/MAPK pathway through Tyr(P) sites in the CH1 region and recruitment of Grb2 (21) , suggesting that each region of Shc has different biological roles.
In this study, we defined the molecular basis and specificity of interaction between ShcB/ShcC and the Trk receptors. We identified that ShcB and ShcC bind to TrkA at Tyr 499 in a Tyr(P)-dependent manner. In a similar way, ShcB and ShcC bind to rat TrkB at Tyr 515 . The PTB domain of ShcB, but not the SH2 domain, mediates binding to the Trk receptors. More importantly, ShcB/ShcC expression in PC12-, TrkB-, or TrkCexpressing cells supports NGF/BDNF/NT-3-dependent phosphorylation of ShcB/ShcC, resulting in Grb2 binding and enhanced MAPK activation. Furthermore, both ShcB and ShcC are activated in mouse cortical neurons upon stimulation with BDNF and NT3, indicating that they are endogenous targets of the Trk receptors in primary neurons. Interestingly, additional tyrosine-phosphorylated proteins were identified in immunoprecipitation reactions with anti-ShcB/ShcC antibodies in primary cortical neurons, suggesting that these molecules are additional downstream targets of neurotrophin-activated ShcB/ShcC in primary neurons.
EXPERIMENTAL PROCEDURES
Materials and Antibodies-Mouse NGF (2.5 S) was purchased from Harlan Bioproducts for Science. Recombinant BDNF and NT-3 were gifts from A. A. Welcher (Amgen Inc). The anti-hemagglutinin (HA) antibody, 3F10, was from Roche Molecular Biochemicals. Anti-c-Myc antibodies were produced by a hybridoma, 9E10 (22) , grown as ascites tumors in 4 -6-week-old female BALB/c mice. Rabbit antibodies to the C-terminal 14 residues of TrkA (J203) were prepared using standard techniques (13) . Monoclonal anti-Trk antibodies (MCTrks) were purchased from Santa Cruz Biotechnology. Rabbit antiserum to the CH1 domain of ShcB (amino acids 310 -477) (namely anti-ShcB GP) was the generous gift of Tony Pawson (Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada) (8) . Independently, we also made a rabbit antiserum to a peptide of 15 amino acid residues (449 -463) (8) from ShcB (namely anti-ShcB) (Genemed Synthesis Inc., San Francisco, CA), which was affinity-purified by standard procedures using the ShcB peptide coupled to NHS-activated Sepharose (Amersham Biosciences). The rabbit antibodies to Grb2, N-Shc (ShcC), and Fyn were purchased from Santa Cruz Biotechnology. The mouse monoclonal antibody to Src (Mb327) (23) was the gift of Joan S. Brugge (Department of Cell Biology, Harvard Medical School, Boston, MA). The rabbit antibodies against normal and activated MAPK were purchased from New England Biolabs and Promega, respectively. The horseradish peroxidase-coupled anti-phosphotyrosine antibody (RC20) was from Transduction Laboratories.
Cells and Transfections-COS-7 African green monkey kidney cells (24) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum. For transfection, a total of 4 ϫ 10 5 cells were seeded into 60-mm dishes. The next day, cells were re-fed and transfected with 2 g each of indicated recombinant DNA constructs with LipofectAMINE 2000 (Invitrogen). After 24 -48 h of transfection, untreated cells and cells treated with neurotrophin (NGF, BDNF, or NT-3; 100 ng/ml, 5 min) were lysed in Nonidet P-40 lysis buffer (1% Nonidet P-40, 137 mM NaCl, 10% glycerol, 2 mM EDTA (pH 8.0), 20 mM Tris (pH 8.0)) containing 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, plus 2 g/ml leupeptin and 10 g/ml aprotinin.
PC12 rat adrenal pheochromocytoma cells (24) and the derived cell lines, including nnr5 (14, 25) , nnr5-TrkA (14, 25) , nnr5-TrkB (25) , and nnr5-TrkC, were maintained in DMEM containing 5% fetal calf serum and 5% horse serum. nnr5 cells are nonresponsive to neurotrophin stimulation. nnr5-TrkA and nnr5-TrkB cells stably express ϳ50 -100-fold higher levels of TrkA and TrkB than PC12 cells, respectively (10, 13) . nnr5-TrkC cells were made by pcDNA-TrkC (rat) transfection into nnr5 cells and selecting for stable expression. These cells express ϳ10 -30-fold higher levels of TrkC than levels of TrkA on PC12 cells (data not shown). For transfection, cells were seeded at the concentration of 6 ϫ 10 5 cells/60-mm dish and, the next day, cells were transfected as described above. Cell lysates were prepared as described above.
High-five insect cells were cultured in Grace's complete medium (Invitrogen) containing 10% fetal bovine serum (FBS). Recombinant baculovirus expressing wild type TrkA, with a HA N-terminal tag, was made as described previously (10, 13) . Cells were infected with the recombinant baculoviruses (10, 26) . After stimulation with 100 ng/ml NGF for 10 min, cells were lysed in Nonidet P-40 lysis buffer as described above. Clarified lysates were assayed for total protein (BioRad D c protein assay kit). The levels of receptor expression were determined by Western blotting with the anti-HA antibody, 3F10.
Expression Constructs-The wild type rat TrkA receptor cDNA was used as the template to make the following constructs. The mutants of TrkA, including S3 (a deletion of ⌬ 493 IMENP 497 ), S8 (Y499F), S9 (Y794F), and S11 (kinase-inactive mutation, K547A), have been previously described (10, 13, 14) . Similar mutants in rat TrkB (accession number NM_012731) were created using a similar strategy at the following sites: BS3 (a deletion of ⌬ 499 VIENP 513 ), BS8 (Y515F), BS9 (Y816F), and BS11 (kinase-inactive mutation, K573A). All wild type and mutant receptors contain an N-terminal HA epitope and were cloned into the mammalian expression vector, pCMX (10) . All constructs were generated by standard techniques and were confirmed by DNA sequencing (Robarts Research Institute).
Wild type TrkA was also cloned into the baculoviral expression vectors, pBacPAK8 (10), as described before (10, 13) . The ICD of wild type and mutant TrkA receptors (S3, S8, S9, and as described above) fused to the yeast GAL4 activation domain in pAS2.1 (CLONTECH) have been previously described (27) . For yeast two-hybrid screening, constructs containing the ICD region of rat wild type TrkB (amino acid residues 458 -821) and TrkC (amino acid residues 458 -825) fused to the yeast GAL4 activation domain were created in pAS2.1. The ICD of TrkB was cut from pGEX-TrkB/ICD (10) with EcoRI and SalI, and the excised 1.1-kb fragment was ligated into the respective sites of pAS2.1. The ICD fragment of TrkC was cut from pCMX-TrkC (10) with HindIII and XbaI and cloned into the same sites of pSE280 (Invitrogen). As one SalI site is in the polylinker of pSE280, a SalI fragment containing the ICD region of TrkC was ligated into the SalI site of pAS2. (28) . The mouse cDNA for the ShcC p55 isoform was amplified from adult mouse brain RNA by PCR with primers corresponding to sense (5Ј-GTCGACGAGTGCCACCAGGAAGAGCCG-3Ј) and antisense (5Ј-GGATCCTCAGGGTTTCCTCTCCACTGGTT-3Ј) sequence reported in the GenBank TM (accession number NM_009167). PCR products were cut out with SalI and BamHI and then ligated into appropriate sites of pRK5 generating an N-terminal fusion with Myc. The ShcB and ShcC sequences were confirmed by DNA sequencing (Robarts Research Institute).
The PTB and SH2 domains of ShcB were amplified by PCR using pACT2-ShcB as a template. The PCR primers for the PTB domain were sense (5Ј-GGAATTCTGGGGCCCGGGGTCTCCTA-3Ј) and antisense (5Ј-CCGCTCGAGCTCCTCGTCCCCCCAGGC-3Ј). The primers for the SH2 domain were sense (5Ј-GGAATTCTGGTACCACGGCCGGATGA-3Ј) and antisense (5Ј-CCGCTCGAGCCGTGAGACCACGCCA-3Ј). Fusion vectors for GST-ShcB PTB and GST-ShcB SH2 were constructed by cloning each restriction fragment into appropriate sites of pGEX-4T (Amersham Biosciences). The sequence was confirmed by DNA sequencing (Robarts Research Institute). The GST fusion proteins for GST-ShcB full-length, GST-ShcB PTB, and GST-ShcB SH2 were obtained by isopropyl-1-thio-␤-D-galactopyranoside induction of Escherichia coli BL-21 cells harboring the corresponding constructs and purified from bacterial lysates with glutathione-Sepharose according to the instructions of the manufacturer (Amersham Biosciences).
Co-immunoprecipitation, SDS-PAGE, and Western Blot AnalysisFor ShcB binding assays, COS cells were co-transfected with GST-fused ShcB in pEBG-3 and HA-tagged wild type and mutant Trk receptors in pCMX. Cells were stimulated with NGF or BDNF at 100 ng/ml for 5 min. Cell lysates, prepared in Nonidet P-40 buffer, were precipitated by glutathione-Sepharose beads. GST-bound proteins were resolved on a SDS-polyacrylamide gel and transferred to Immobilon-P. Western blotting was performed with anti-HA 3F10 antibody (1:3000 dilution) as described before (13) . For ShcC binding assays, COS cells were cotransfected with Myc-tagged p55 ShcC in the pRK5 vector and HAtagged wild type and mutant Trk receptors in pCMX. Cells were stimulated as described above. Cell lysates, prepared in Nonidet P-40 buffer, were precipitated by 2 g of anti-Myc antibody, 9E10. The bound proteins were resolved on a SDS-polyacrylamide gel, and Western blotting was performed with anti-HA 3F10 antibody.
To define the region of ShcB that mediates binding to TrkA, equal amounts (ϳ5 g) of purified GST fusion proteins (including GST, GSTShcB full-length, GST-ShcB PTB, GST-ShcB SH2, and GST-ShcA PTB) were mixed with 300 g of insect cell lysates containing baculovirus expressed wild type TrkA (10). After incubation overnight at 4°C, beads were washed twice with Nonidet P-40 lysis buffer and once with cold phosphate-buffered saline. The bound proteins precipitated by glutathione-Sepharose beads were resolved on SDS-PAGE followed by Western blotting with 3F10 antibody (1:3000). Purified GST and GST-ShcA PTB served as the negative and positive controls, respectively.
For tyrosine phosphorylation assays, the transfected COS cells were stimulated with neurotrophin (NGF, BDNF, or NT-3 at 100 ng/ml for 5 min) and lysed in Nonidet P-40 lysis buffer containing 1 mM sodium orthovanadate. Equal amounts of protein (200 g) were immunoprecipitated with 9E10 anti-c-Myc antibodies (2 g). After washing, the bound proteins were resolved on a 10% SDS-polyacrylamide gel and transferred to an Immobilon-P membrane. Proteins were visualized by an anti-phosphotyrosine antibody, RC20 (1:2000) .
For MAPK assays, Myc-ShcB and Myc-ShcC were overexpressed in PC12 and nnr5-TrkC cells. After 5-7 days of expression, cells were washed extensively by serum-free medium and then stimulated with NGF (50 ng/ml, 2 min) and NT-3 (50 ng/ml, 3 min), respectively. Cell lysates were prepared, and 50 g of proteins were analyzed by 10% SDS-PAGE. MAPK activation was detected by using an anti-active MAPK antibody (1:5,000) (Promega) and horseradish peroxidase antirabbit antibody (1:10,000). The membrane was stripped as described below and then re-blotted with the anti-normal MAPK antibody (1: 10,000) (Cell Signaling Technology). Blots were analyzed by densitometric scanning (Bio-Rad, model GS-700) and were normalized for differences in protein loading per lane. Data shown in When indicated, membranes were stripped at 45°C for 15 min in 62.5 mM Tris-HCl (pH 6.8) containing 1% SDS, 100 mM ␤-mercaptoethanol and reprobed with the indicated antibodies.
Yeast Two-hybrid System-The yeast strain PJ69 -4A (MAT␣, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4 gal80, LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ) was a gift from Philip James (University of Wisconsin, Madison, WI) (29) . All yeast media were from CLON-TECH. 3-Aminotriazole (3-AT) was from ICN.
For yeast two-hybrid screening, the ICDs of wild type TrkB and TrkC, fused to the GAL4 DNA-binding domain in the pAS2 vector (Trp marker), were used as bait plasmids. Transformed PJ69 -4A bait strains were then co-transformed with a human mammary gland Matchmaker activation domain containing cDNA library (Leu Marker) (CLONTECH). Transformed yeast cultures were plated onto sc medium minus Leu, Trp, and His containing 20 mM 3-AT (ICN). After 5 days of culture at 30°C, positive interactors were picked to grid plates containing sc medium minus histidine, adenine, leucine, and tryptophan (HALT) to eliminate false positives. To drop out the binding domain plasmid, yeast clones were grown in media minus leucine for at least 3 days. The yeast DNA was then isolated by standard procedure and transformed into E. coli HB101 strain by electroporation using standard procedure (10) . To further select for activation domain-containing plasmids, colonies were allowed to grow on M9 media (15) lacking leucine. E. coli DNA was then prepared for DNA sequencing (Robarts Sequencing Facility). A total of 2 ϫ 10 6 clones were screened. For binding assays in yeast, the ICDs of wild type and mutant TrkA (S3, S8, S9, and S11), fused to the GAL4 DNA-binding domain in pAS2, were used as baits. Transformed PJ69 -4A bait strains were then co-transformed with ShcB in the pACT2 vector (CLONTECH). Cultures were plated on media minus Leu and Trp (LT), and growing colonies were cultured overnight in liquid LT. To select for colonies expressing the HIS and ADE reporters, where ShcB interacts with TrkA, cultures were then grown on HALT with 40 mM 3-AT. The pACT2 vector alone served as the negative control. For positive controls, pACT2-ShcA and Grb2 constructs were used because they interact well with the Trk receptors (10) .
Cortical Neurons-Cortical neurons were isolated from embryonic day 16 CD1 mice using a standard procedure (30) with minor modifications. Briefly, embryo forebrains were dissected in Hanks' balanced salt solution (HBSS) (Invitrogen). Pieces of cerebral cortices were collected and mechanically triturated in 2 ml of HBSS plus 10% FBS by passing through wide and heat-narrowed Pasteur pipettes 15 times. Dissociated cells were passed through a low binding 70 M cell strainer (Falcon) and then washed in 10 ml of HBSS plus 10% FBS. Live cells were counted by trypan blue exclusion assay in a hemocytometer. A total of 3 ϫ 10 6 cells in media containing 54% neurobasal medium, 36% DMEM/F-12, and 10% FBS were plated onto 60-mm dishes precoated with 100 g/ml poly-D-lysine (Sigma). Cells were allowed to attach for 1 h. Cells were extensively washed with HBSS and then cultured in media containing neurobasal medium (60%) plus DMEM/F-12 (40%), 15 mM Hepes (pH 7.4) supplemented with glucose (6 g/liter), insulin (10 mg/liter), apotransferrin (20 mg/liter), putrescine (61 M), progesterone (20 M), and sodium selenite (30 nM) (all from Sigma), for 4 days at 37°C. The medium was changed every 2 days. One hour prior to cell harvest, endogenous neurotrophins were removed by washing twice with medium. After stimulation with medium alone or 100 ng/ml NGF, BDNF, or NT-3 (5 min), cells were washed with cold phosphate-buffered saline containing 1 mM sodium orthovanadate and then lysed in ice-cold Nonidet P-40 lysis buffer containing 1 mM sodium orthovanadate as described above. Lysates containing 400 g of protein were immunoprecipitated with anti-ShcB GP antibody (1:100) (8) and anti-N-Shc antibody (1:100) (Santa Cruz Biotechnology). The immunoprecipitated proteins were visualized with the anti-Tyr(P) antibody RC20. The membranes were stripped at 45°C for 15 min in stripping buffer as described above and then re-blotted with anti-ShcB (1:2000), anti-N-Shc (1:500), and anti-Src (0.1 g/ml). To test the specificity of ShcB-Src interaction in cortical neurons, lysates (400 g) were also immunoprecipitated with purified normal rabbit IgG (2 g/ml), anti-ShcB GP (1:100), preimmune serum (1:100), anti-ShcB (1:100), and anti-Src (2 g/ml). After resolving by SDS-PAGE, proteins were visualized with the anti-Src antibody (1 g/ml). To test the phosphorylation of Src and Fyn in cortical neurons, lysates containing 400 g of protein were immunoprecipitated with anti-Src (2 g/ml) and anti-Fyn antibody (1:100) (Santa Cruz Biotechnology). The immunoprecipitated proteins were visualized with the anti-Tyr(P) antibody RC20.
To test ShcB/ShcC-Trk interaction in cortical neurons, lysates (1 mg) were immunoprecipitated with the anti-ShcB (2 g/ml) (purified) or anti-Trk (J203; 1:250) antibodies. The precipitated proteins were resolved in SDS-PAGE and visualized with the anti-Trk (MCTrk) antibody (1:200; Santa Cruz Biotechnology) or anti-N-Shc (1:100; Santa Cruz Biotechnology). To detect the Trk activation by neurotrophin stimulations, the same lysates (200 g) were immunoprecipitated with anti-Trk antibody J203 (1:250) and then blotted with the anti-Tyr(P) antibody RC20 (1:2000) .
RESULTS

Isolation and Phosphorylation of the ShcB Adapter by the
Trk Receptors-To identify additional binding partners of the neurotrophin Trk receptors, we have performed several yeast two-hybrid screens using the ICDs of the Trk receptors as baits and commercially available cDNA libraries. In this report, we characterize the isolation of a clone bearing the ShcB cDNA from a human mammary library (CLONTECH) in the pACT2 vector that showed strong interaction with the ICD of TrkC (data not shown). The human ShcB cDNA without the CH2 region (His 111 to Pro 573 , equivalent to the mouse ShcB sequence in Ref. 8 ) was excised or amplified by PCR from the pACT2 cDNA plasmid, subcloned, and used in the following experiments. Although the isolation of this clone was not unexpected, because ShcA is well known to interact with the Trk receptors, it is highly relevant because the ShcB and ShcC adapters are more highly expressed than ShcA in the nervous system (1, 18) . Thus, this provided an opportunity to investigate whether there are differences in the interaction and/or activation of the different Shc adapters by the Trk receptors, particularly in light of a previous report that ShcB did not interact strongly with or become strongly activated by either TrkA or TrkB (1) .
Because Trk activation results in tyrosine phosphorylation of target proteins, we first determined whether ShcB was tyrosine-phosphorylated by TrkA, TrkB, and TrkC stimulation. Myc-tagged ShcB and HA-tagged Trk constructs were co-transfected into COS cells, and lysates were immunoprecipitated with the anti-Myc antibody, 9E10, followed by Western blotting with an anti-phosphotyrosine antibody, RC20. As shown in Fig.  1 , ShcB was phosphorylated by TrkA, TrkB, and TrkC (Fig. 1A,  upper panel) . Moreover, Western blotting with anti-HA antibodies, 3F10, demonstrates that all three Trks co-immunoprecipitate with ShcB to similar levels (Fig. 1A, middle panel) . The doublet Trk bands in Fig. 1 (A and B) , and other figures described below, indicate different glycosylation states of the receptors (10, 26) . The lower panel indicates that ShcB was expressed to similar levels in each transfection (Fig. 1A, bottom  panel) . These results suggest that ShcB can be phosphorylated by TrkA, TrkB, or TrkC and, more importantly, that ShcB can interact with all three Trk receptors in transfected COS cells.
To further confirm the specificity of ShcB phosphorylation by Trk activation, we co-expressed ShcB with wild type and kinase-inactive TrkA in COS cells. As expected, co-transfection with kinase-inactive TrkA completely diminished phosphorylation of ShcB (Fig. 1B, lane 4) . ShcB could be phosphorylated in COS cells constitutively when co-expressed with wild type TrkA (Fig. 1B, lane 2) ; however, additional NGF stimulation did significantly enhance the phosphorylation of ShcB (Fig. 1B,  lane 3) . These results further demonstrated that ShcB specifically interacts with kinase-active TrkA in COS cells.
To further define the ability of ShcB to bind to the Trk receptors, we employed GST fusion techniques. ShcB was fused with GST in a mammalian expression vector, pEBG3. GSTShcB and HA-Trks were then co-expressed in COS cells. After stimulation with neurotrophins, cells were lysed and GSTShcB was precipitated with glutathione-Sepharose. Co-precipitated Trk receptors were visualized with anti-HA antibody 3F10. As shown in Fig. 1C , no visible band was seen when GST-ShcB was expressed alone (top panel, lane 1), whereas bands corresponding to TrkA, TrkB, and TrkC were detected in co-transfected cell lysates. Stripping and re-blotting with anti-GST antibodies indicate similar levels of GST-ShcB expression in all lanes (Fig. 1C, middle panel) . Similarly, Western blot analysis with anti-HA antibodies showed similar expression levels of the Trk receptors in whole cell lysates (Fig. 1C, lower  panel) . These results, similar to that shown in Fig. 1A (10, 13, (31) (32) (33) . To explore the site of ShcB-TrkA interaction, we employed several mutant Trk constructs, specifically, S8 (Y499F) and S9 (Y794F), which have been shown to affect ShcA/FRS2 and PLC-␥1/CHK binding, respectively (10, 13, 16) . GST-ShcB and HA-tagged TrkA mutants were cotransfected into COS cells, and GST-precipitated proteins were assayed with anti-HA antibodies. As shown in Fig. 2B , GSTShcB bound HA-tagged wild type TrkA and the S9 mutant, respectively (Fig. 2B, top panel, lanes 2 and 5) . The S8 mutation significantly reduced GST-ShcB binding to TrkA (Fig. 2B,  top panel, lane 4) . Similarly, the S3 mutation, which is a deletion of 493 IMENP 497 in rat TrkA, and has previously been shown to affect ShcA and FRS2 binding to TrkA (13), also showed a similar reduction in binding ability of ShcB (Fig. 2B,  top panel, lane 3) . More importantly, the kinase-inactive mu- tation (S11, K547A) completely blocked the binding of ShcB to TrkA (Fig. 2B, top panel, lane 7) . A combination mutation of S8 and S9 also significantly reduced the binding of ShcB to TrkA (Fig. 2B, top panel, lane 6) , which confirmed that Tyr 499 is the binding site of ShcB to TrkA. Stripping and re-probing with anti-GST antibodies detected similar levels of GST-ShcB expression in all lanes (Fig. 2B, middle panel) . Similarly, Western blotting with anti-HA antibodies showed similar expression levels of the TrkA receptors in whole lysates of each co-transfection (Fig. 2B, lower panel) . Taken together, these results indicate that ShcB can bind to TrkA at Tyr 499 in a phosphotyrosine-dependent manner.
As mentioned above, the Shc family contains three members, i.e. ShcA, ShcB, and ShcC, that share a high degree of identity at the amino acid level in the PTB and SH2 domains (8, 17) . To determine whether the ShcC adapter also binds to TrkA at the same site, Tyr 499 , we co-transfected COS cells with a Myctagged ShcC and HA-tagged wild type and mutant TrkA receptors. Lysates prepared 24 h after transfection were used for immunoprecipitation with the anti-Myc antibody, 9E10. Coimmunoprecipitated proteins were identified by Western blotting with the anti-HA antibody, 3F10. As shown in Fig. 3 , ShcC precipitated wild type TrkA strongly and the S9 mutation (Y794F) did not reduce binding, whereas the S8 (Y499F) and S3 (⌬ 493 IMENP 497 ) mutations significantly reduced, and the S11 (K547A) mutation completely blocked, ShcC binding to TrkA. Thus, the binding pattern of ShcC to TrkA is the same as observed for ShcA and ShcB.
ShcB and ShcC Bind to TrkB at Tyr 515 -The ICD region is highly conserved among TrkA, TrkB, and TrkC receptors (34, 35) . Thus, we hypothesized that the interaction between ShcB and TrkB would involve the homologous residue, Tyr 515 , in rat TrkB, which is also involved in ShcA binding (16) . To clearly define this, we made similar mutations in the rat TrkB receptor, namely BS3 (⌬ 499 VIENP 513 ), BS8 (Y515F), BS9 (Y816F), and BS11 (kinase-inactive mutation, K573A). GST-ShcB was co-transfected with HA-tagged wild type or mutant TrkB receptors in COS cells. Cell lysates were precipitated with glutathione-Sepharose and then were analyzed by Western blotting with anti-HA antibodies. As expected, the Y816F (BS9) mutation did not affect ShcB binding to TrkB (Fig. 4A , compare lane 2 with lane 5), whereas the kinase-inactive mutation, K573A (BS11), completely blocked the interaction of ShcB with TrkB (Fig. 4A, lane 6) . Similarly, Y515F (BS8) significantly reduced the binding of ShcB to TrkB (Fig. 4A, lane 4) . As described for TrkA, a deletion mutation of 499 VIENP 513 also reduced ShcB binding to TrkB (Fig. 4A, lane 3) . These results suggest that the homologous residue, Tyr 515 , in rat TrkB is involved in the interaction between ShcB and TrkB.
Using the same approach, we determined the site of ShcC binding to TrkB. Accordingly, Myc-tagged ShcC and HA-tagged TrkB were co-transfected into COS cells. Cell lysates prepared 24 h after transfection were immunoprecipitated with anti-Myc antibody 9E10 and then assayed by Western blotting with anti-HA antibody 3F10. Similar to results described above, the . Single letters are used to indicate amino acids. B, COS cells expressing GST-ShcB and HA-Trk or GST-ShcB alone were stimulated with NGF (100 ng/ ml) for 5 min and cell lysates were prepared. GST-ShcB-bound proteins were pelleted with glutathione-Sepharose, followed by immunoblotting with the anti-HA 3F10 antibody. Membranes were stripped and then re-probed with the anti-GST antibody as indicated. For analysis of Trk expression, cell lysates (50 g) were blotted with the anti-HA 3F10 antibody. Arrows indicate the position of ShcB and the Trks. wt, wild type; Ppt, precipitated. (Fig. 4B, compare lane 2 with lane 5) , whereas the kinaseinactive mutation, K573A (BS11), completely blocked the interaction of ShcC with TrkB (Fig. 4B, lane 6) . Moreover, both Y515F (BS8) and a deletion mutation of 499 VIENP 513 (BS3) significantly reduced ShcC binding to TrkB (Fig. 4B, lanes 3  and 4) . Thus, ShcB and ShcC both bind TrkB receptor at Tyr 515 in a phosphotyrosine-dependent manner.
Y816F (BS9) mutation did not affect ShcC binding to TrkB
ShcB Interacts with TrkA in Yeast-To further confirm the in vivo binding ability of ShcB to TrkA, we used the yeast twohybrid system. ShcB fused with the GAL4 activation domain in the pACT2 vector (containing the Trp marker) and ICD of wild type and mutant TrkA receptor fused to the GAL4 DNA-binding domain in the pAS2 vector (containing the Leu marker) were co-transformed into the yeast strain PJ69 -4A (29) . For controls, ShcA and Grb2, which have been shown to bind both S8 and S9 mutants of TrkA (10), were also included. Cultures were plated on LT. Yeast without any vector did not grow, whereas those containing both pACT2 and pAS2 grew effectively (Fig. 5A) . Colonies growing in LT were then plated on HALT plates containing 3-AT (40 mM) (Fig. 5B ). Cultures containing an empty pACT2 vector died. In contrast, colonies co-transformed with ShcB and wild type TrkA grew well in HALT, indicating that ShcB-TrkA interact well in yeast. The S9 mutation did not affect the interaction between ShcB and TrkA. As expected, both the S3 and S8 mutations significantly reduced ShcB interaction with TrkA, and the S11 mutation failed to interact with ShcB. These results confirm that ShcB binds to TrkA at Tyr 499 in a phosphotyrosine-dependent manner in vivo in yeast.
The PTB Domain of ShcB Mediates Binding to TrkA-As mentioned above, it has been reported that the PTB domain of ShcA and ShcC mediates binding to TrkA (18, 36, 37 ). To determine whether the same region of ShcB also binds the Trk receptors, we made GST fusion proteins for the PTB and SH2 domains of ShcB. High levels of TrkA were expressed by baculovirus in Hi-five insect cells (see Fig. 6, middle panel) . Consistent with previous reports, GST fusion proteins containing the ShcA PTB domain effectively bound TrkA (Fig. 6, top panel,  lane 5) . As expected, a GST fusion protein containing fulllength ShcB also bound TrkA (Fig. 6, top panel, lane 2) . Analysis of the PTB or SH2 fusion proteins indicated that the GST fusion protein containing the PTB domain of ShcB clearly bound TrkA (Fig. 6, top panel, lane 3) to a similar level as compared with full-length ShcB (Fig. 6, top panel, lane 2) . In contrast, GST-ShcB-SH2, like GST protein alone (Fig. 6, top  panel, lane 1) , did not show binding to TrkA (Fig. 6, top panel,  lane 4) . Coomassie staining showed that similar amounts of GST alone and GST fusion proteins were used (Fig. 6, lower  panel) . Thus, the PTB domain, but not the SH2 domain, of ShcB binds to TrkA.
Activated ShcB and ShcC Bind to Grb2-Because activated ShcA interacts with the SH2 domain of Grb2, via YYNS and YVNT motifs in the CH1 region (38), we assayed ShcB-Grb2 interactions by co-immunoprecipitation assays. For these studies, we used an nnr5 cell line, which does not express endogenous Trk receptors, that was generated to stably express high levels of TrkB, termed nnr5-TrkB (13, 25) . Accordingly, ShcB was transfected into nnr5-TrkB cells to assay BDNF-dependent ShcB/Grb2 interactions. Untransfected nnr5 cells were used as a negative control. BDNF-stimulated or unstimulated cell lysates were immunoprecipitated with anti-Grb2 antibodies followed by Western blotting with the anti-ShcB antibody. As shown in ), BS8 (Y515F), BS9 (Y816F), and BS11 (kinase-inactive mutation, K573A) were used. wt, wild type; Ppt, precipitated.
band was observed in BDNF-stimulated nnr5-TrkB cells, suggesting that ShcB is endogenously expressed in nnr5-TrkB cells. Consistent with previous results, our data confirmed that only activated ShcB interacts with Grb2.
ShcC also possesses conserved YYNS and YVNT motifs in the CH1 region (8) . To test the ability of activated ShcC binding to Grb2, Myc-ShcC was also transfected into nnr5-TrkB cells and the BDNF-stimulated cell lysates were immunoprecipitated with the anti-Grb2 antibodies followed by Western blotting with the 9E10 antibody. The results showed that only activated ShcC binds to Grb2 (Fig. 7B) . As nnr5-TrkB cells have already expressed high levels of TrkB, co-transfection of TrkB did not enhance the ShcC-Grb2 interaction (Fig. 7B, lane 3) .
To test TrkC activated ShcB/Grb2 and ShcC/Grb2 interactions, we employed nnr5-TrkC cells. ShcB or ShcC was transfected alone or co-transfected with TrkC into the cells. After 24 h of transfection, cells were stimulated with 100 ng/ml NT3 for 10 min. NT-3 stimulation can activate ShcB-Grb2 interaction in nnr5-TrkC cells (Fig. 7C) . As TrkC expression in these cells is quite low, co-transfection of TrkC was used to enhance phosphorylation of ShcB and increase interaction of ShcB with Grb2 (Fig. 7C, lane 3) . Similarly, ShcC-Grb2 interaction was observed by NT-3 stimulation in nnr5-TrkC cells (Fig. 7D) .
Taken together, these data demonstrate that both ShcB and ShcC can be activated by NT-3 through TrkC and that activated ShcB and ShcC both interact with Grb2. This supports that all three Shc proteins can activate downstream signaling (i.e. Grb2 activation) in response to stimulation by the neurotrophin Trk receptors.
Overexpression of ShcB and ShcC Activates MAPK in PC12 Cells-It is well known that Trk-Shc interactions are an implicated route to activate Ras-dependent MAPK in response to neurotrophin stimulation. As nnr5-TrkB cells express 100 times higher levels of Trk receptors than PC12 cells (13), we could not detect differences in the level of neurotrophin-dependent MAPK activation between cells left untransfected and/or transfected with ShcB (data not shown). Thus, we assayed changes in NGF-dependent MAPK activation in PC12 cells transfected with ShcB and ShcC. Cells were stimulated with 50 ng/ml NGF for 2 min to activate TrkA signaling. As expected, activated MAPK was detected in NGF-stimulated PC12 cells (Fig. 8A, lanes 2 and 5) . Importantly, overexpression of ShcB could enhance the level of neurotrophin-dependent MAPK activation (Fig. 8A, compare lane 2 with lane 3) , suggesting that ShcB stimulation results in the activation of MAPK. Similarly, overexpression of ShcC could also enhance NGF-dependent MAPK activation in PC12 cells (Fig. 8A , compare lane 6 with lane 5).
As described above (Fig. 7) , ShcB and ShcC also bind Grb2 following NT-3 stimulation in nnr5-TrkC cells. Thus, we similarly assayed NT-3-dependent MAPK activation following ShcB and ShcC overexpression. As expected, we found that NT-3 stimulation activates MAPK at low levels in untransfected nnr5-TrkC cells (Fig. 8B, lanes 2 and 4) . However, both ShcB and ShcC transfection enhanced MAPK activation in response to NT-3 stimulation (Fig. 8B, compare lane 3 with  lane 2 and lane 5 with lane 4) . The results further confirm that ShcB and ShcC interact well with TrkC and enhance NT-3-dependent MAPK activation.
To more precisely determine whether ShcB and ShcC overexpression can enhance MAPK activation, we repeated the above experiments three to five times. As shown in Fig. 8C , NGF stimulates MAPK activation to levels ϳ1.5 times higher than unstimulated cells. By comparison, overexpression of ShcB and ShcC in PC12 cells significantly increased these levels to ϳ2 and 2.5 times higher than cells transfected with vector alone (p Ͻ 0.05) (Fig. 8C) . Similarly, ShcB and ShcC ), S8 (Y499F), S9 (Y794F), and S11 (K547A)) TrkA receptors, in pAS2, were transfected or co-transfected with ShcB, in pACT2, into yeast strain PJ694A. For controls, ShcA and Grb2 were also included. Cells were plated on LT (A) and sc medium minus Leu, Trp, His, and Ade plus 40 mM 3-AT (HALT) (B) . WT, wild type; Non, not cotransfected with pAct2.
FIG. 6.
In vitro binding of ShcB domains to TrkA. Bacterially expressed GST or GST-ShcB (full-length, PTB domain, and SH2 domain) fusion proteins (5 g) were assayed for precipitation (Ppt) of insect cell lysates (300 g) containing baculovirus expressed HA-tagged wild type TrkA. Bound proteins were precipitated with glutathioneSepharose followed by blotting with the anti-HA antibody. Arrows indicate the positions of TrkA (gp110, gp140). To test protein loading, cell lysates of insect cells containing baculovirus expressed HA-tagged wild type TrkA was detected with the anti-HA 3F10 antibody (middle panel). The same value of GST and GST fusion proteins was applied to another gel and then stained with Coomassie Brilliant Blue to test the amount of GST proteins loaded (bottom panel).
overexpression in nnr5-TrkC cells increased levels of MAPK activation to levels ϳ2 and 2.5 times higher than vector alone (p Ͻ 0.01) (Fig. 8D) .
ShcB and ShcC Are Activated in Primary Cortical Neurons-To assay neurotrophin-dependent activation of ShcB and ShcC in primary neurons, we assayed tyrosine phosphorylation of ShcB and ShcC in primary mouse cortical neurons in response to BDNF and NT-3 stimulation. Primary rodent cortical neurons (E16), which express high levels of TrkB and TrkC receptors, were cultured for 4 days in the absence of growth factors. Prior to lysis, cortical neurons were washed for 1 h and then stimulated with medium alone, NGF, BDNF, or NT-3 at a concentration of 100 ng/ml for 5 min. As shown in Fig. 9 (top panel), both ShcB and ShcC are phosphorylated in cortical neurons by BDNF and NT-3 stimulation (indicated by the solid arrows). As expected, endogenous ShcB is larger than the positive control containing HA-ShcB in transfected COS cells. This reflects the absence of the N-terminal CH2 region in our ShcB cDNA construct (Fig. 9, top and second panels, lanes 6 and 12) . NGF stimulation did not activate ShcB and ShcC, as the TrkA receptor is not expressed in cortical neurons (36, 39) . Stripping and re-probing the blots with either anti-ShcB GP (8) or anti-N-Shc (ShcC) antibodies confirmed the identity of the ShcB and ShcC bands (Fig. 9, second and third panels, respectively) . Importantly, these results suggest that both ShcB and ShcC are involved in the signal transduction pathways of neurotrophin-activated Trk receptors in cortical neurons.
Interestingly, we also identified two additional tyrosinephosphorylated targets, ϳ60 and 75 kDa, that were co-immunoprecipitated with the anti-ShcB GP antibody in neurotrophin-stimulated cortical neurons (Fig. 9, stippled arrows) . The smaller protein, pp60, was also identified in anti-ShcC immunoprecipitates. These targets were specific to cortical tissues as they were not detected in ShcB and Trk co-transfected COS cell lysates (data not shown) despite significant Trk-dependent tyrosine phosphorylation of ShcB (Fig. 1A) . The identity of these proteins is presently unknown. The possibility that the 60-kDa protein represents a member of the Src family of soluble tyrosine kinases was considered, particularly because the Fyn kinase has been shown to associate with activated TrkB in primary rat cortical neurons (40) . Interestingly, we found that ShcB and ShcC did co-immunoprecipitate with c-Src, albeit constitutively, in cortical cell lysates (Fig. 9, fourth panel) . To test the specificity of the Src-Shc interactions, we tested immunoprecipitations with a second anti-ShcB antibody that we generated and affinity-purified against a peptide specific for ShcB (449 -463). Both anti-ShcB antibodies specifically co-immunoprecipitated Src in comparison to either normal rabbit IgGs or preimmune sera (data not shown). These results indicate that ShcB constitutively interacts with the Src proteins. Probably, however, because Src and Fyn are constitutively tyrosine-phosphorylated in mouse cortical cultures, and neither BDNF nor NT-3 stimulation increased their phosphorylation (Fig. 9B) , it is likely that the tyrosine-phosphorylated protein detected in our ShcB/ShcC immunoprecipitations represents another protein independent of the Src family of kinases. To demonstrate ShcB/ShcC-Trk interaction in cortical neurons, additional co-immunoprecipitations using E16 lysates were performed. First, we determined the activation of cortical neurons following neurotrophin stimulation. Lysates were immunoprecipitated with the anti-Trk antibody J203, and the precipitated proteins were assayed with the anti-Tyr(P) antibody RC20. As expected, Trk was activated in cortical neurons stimulated with BDNF and NT-3 but not in nonstimulated and NGF-stimulated cultures (Fig. 10, top panel) . Using the same lysates (1 mg), proteins were immunoprecipitated with the anti-ShcB antibody and Western blots were analyzed with a monoclonal anti-Trk (MCTrk) antibody. As expected, ShcB-Trk interaction could be detected only in lysates from cortical neuron stimulated with BDNF and NT-3, whereas such interaction was not observed in nonstimulated and NGF-stimulated cortical neurons (Fig. 10, second panel) . To analyze ShcC-Trk interactions in cortical neurons, proteins were immunoprecipitated by the rabbit anti-Trk antibody J203 (27) and Western blots assayed with anti-ShcC antibodies. As shown in Fig. 10 (third panel) , ShcC and Trk co-immunoprecipitate in lysates prepared from cortical neurons stimulated with BDNF and NT3 but not from nonstimulated and NGF-stimulated lysates. The Trks are expressed at similar levels in each lane of unstimulated and stimulated cortical neurons (Fig. 10, bottom panel) . These results further indicate that ShcB/ShcC-Trk interactions form in mouse cortical neurons in a neurotrophin-and phosphotyrosine-dependent manner. ShcA, ShcB, and ShcC Share One Site to Bind to the Trk Receptors-Three Shc proteins, ShcA, ShcB, and ShcC, share a similar structure and contain CH2, PTB, CH1, and SH2 domains (8, 17) . In this study, we defined that ShcB and ShcC bind to the same site on TrkA, Tyr 499 , and TrkB, Tyr 515 , consistent with previous reports of ShcA binding to TrkA at Tyr 499 . Thus, all three Shc proteins use the same site to bind to the Trk receptors. This conservation in structure and binding properties may be very important for ShcA, ShcB, and ShcC to be activated by the Trk receptors, as there are obvious differences in the temporal expression of ShcA and ShcC at different stages of cortical neuron development in the brain (1, 9, 18, 20) . Thus, activation of one Shc adapter could be replaced by the activation of another in different tissues or at different stages during development. Our results provide a molecular structural basis by which Trk binding of the Shc proteins can be exchanged. In this respect, ShcA is expressed embryonically but not in the adult brain, whereas ShcC expression is lower in the embryonic brain and increases post-natally (9) .
We have shown that the PTB domain of ShcB, as previously shown for ShcA (41) , mediates binding to TrkA suggesting that this domain also binds TrkB and TrkC. The PTB domains of the Shc proteins are very conserved in different species and different Shc proteins (8, 17) . The amino acid sequence of the mouse ShcB PTB domain is 86% identical to that of human ShcB and 94% identical to rat ShcB (1, 8, 17) . The PTB domains of ShcA, ShcB, and ShcC are also very highly conserved (over 70% amino acid identical to each other) (8, 17) . This would provide a good explanation for how the Shc proteins bind the same site on the Trk receptors. Although a previous report suggested that ShcB is poorly activated by the Trk receptors in transfected 3T3 cells (1), we find that stimulated TrkA, TrkB, and TrkC receptors can bind, phosphorylate, and activate ShcB either in transfected COS, PC12, and nnr5 cells or in primary neurons. The discrepancy between our data and the previous report using a longer human ShcB cDNA (1) is not entirely clear, but may represent differences in cell types, levels of expression, and/or the length of the N-terminal sequence of our respective clones. The mouse ShcB cDNA used in this study (lacking the N-terminal CH2 region) contains amino acid sequence between His 111 and Pro 573 , identical to the sequence reported in the full-length mouse ShcB sequence (8, 17) . In comparison, the human ShcB clone used by Nakamura et al. (1) contains an additional 39 N-terminal residues, which are significantly different from the comparable sequence in the 5Ј end of mouse ShcB (8, 17) . Although it is not clear if these differences reflect significant N-terminal divergence between mouse and man, it is possible that the difference in N-terminal length and/or sequence with our mouse ShcB clone may account for the differences in our respective abilities to detect Trk interaction.
ShcB and ShcC Signaling Is Involved in MAPK ActivationShcB activation by the three Trk receptors is a very important observation, as all three Shc proteins are thought to serve different roles in neural development (9, 16, 19) . In this respect, ShcA is present in neural progenitor cells and is thought to facilitate their proliferation, whereas ShcC is primarily expressed in post-mitotic neurons and is thought to be important to their survival/differentiation (17) . For ShcB, its role has been best described so far in mice carrying a null mutation in which a specific loss of peptidergic and non-peptidergic sensory neurons, as well as TrkA-positive fibers, in the dorsal root ganglion have been observed (8) . Moreover, although ShcC Ϫ/Ϫ mice show no gross developmental abnormalities, mice lacking both ShcB and ShcC show a significant loss of neurons in the superior cervical ganglia (SCG) that is not observed in mice lacking either ShcB or ShcC alone (8) . This suggests that ShcB and ShcC serve redundant roles in SCG development and/or survival. Interestingly, endogenous ShcA expression in the SCG of ShcB Ϫ/Ϫ ShcC Ϫ/Ϫ mice cannot support the survival and/or differentiation of these neurons (8) , consistent with a model that the Shc adapters serve different roles in developing neurons, probably mediated through unique protein-protein interactions.
Although it is becoming increasingly evident that the Shc proteins likely serve some specificity in intracellular interactions, it is also clear that ShcA and ShcC, as well as ShcB (this study), can bind to the adapter protein Grb2 in response to tyrosine kinase activation. Phosphorylation of two Tyr-X-Asn motifs in the CH1 domain of the Shc adapters serves as the binding sites to recruit the SH2 domain of Grb2 to the receptor complexes (38) . Grb2, as a multifunctional signaling adapter, can associate through its SH3 domains with multiple intracellular targets including the Ras guanine nucleotide exchange factor Sos1 and Gab-1 (10, 11, (42) (43) (44) . Active Shc⅐Grb2⅐Sos complexes can, in turn, stimulate MAPK and PI 3-kinase via Ras, whereas Grb2⅐Gab-1 complexes facilitate the activation of PI 3-kinase. Both MAPK and PI 3-kinase activation are associated with neurotrophin-dependent cell survival and neurite outgrowth (42) (43) (44) . Our observation of enhanced neurotrophindependent activation of MAPK in ShcB-and ShcC-overexpressing PC12 and nnr5-TrkC cells is consistent with a role of ShcB and ShcC in supporting cell survival and neuritogenesis in response to the neurotrophins.
ShcB and ShcC Activation in Primary Cortical NeuronsNull mutations in the ShcB and ShcC loci have shown an important role for the ShcB/C adapters in the development and/or survival of the sensory neurons in the dorsal root ganglia and the sympathetic neurons in the SCG (8) . However, because both ShcB and ShcC are highly expressed in the brain (1, 18) , it is likely that both serve additional roles in neurotrophin signaling in the central nervous system as well. To this end, we assayed primary mouse cortical neurons, which express TrkB and TrkC receptors (45, 46) , for neurotrophin-dependent tyrosine phosphorylation of ShcB and ShcC. Importantly, our data clearly shows that BDNF and NT-3 stimulate the tyrosine phosphorylation of ShcB and ShcC in primary mouse cortical neurons. Moreover, we have shown co-immunoprecipitation between endogenous ShcB/ShcC and the Trk receptors in neurotrophin-stimulated post-mitotic mouse cortical neurons, suggesting a role for the ShcB and ShcC adapters in neuronal signaling and development in the brain. Although ShcC is exclusively expressed in the brain, in particular, in mature neurons (1, 9) , ShcB is expressed much earlier during the period of cortical neurogenesis, which occurs between E11 and E17 in the mouse. Specifically, Sakai et al. (8) have detected ShcB expression as early as E12 in the brain, which remains stable until at least 12 weeks post-natally. Although no gross developmental losses were reported in the brains of ShcB Ϫ/Ϫ mice (8), it is likely that ShcB activation serves a role in cortical neuron development and/or function that remains to be understood.
Preliminary efforts to assay ShcB activation in cortical neurons have indicated that two proteins, pp60 and pp75, are tyrosine-phosphorylated and co-immunoprecipitate with BDNF-and NT-3-activated ShcB. The smaller protein is also detected in ShcC co-immunoprecipitates. Although we cannot detect the same bands in ShcB/C and Trk co-transfected COS cells, we cannot yet conclude that these two targets are specific to neural tissues because the ShcB cDNA used in our transfection studies lacked the N-terminal CH2 domain. Thus, these two targets may be specific to neurons or may be CH2 domainbinding proteins. The identification of the ShcB/ShcC-interacting proteins, pp60 and pp75, will be necessary to examine the role of these proteins in neurotrophin-dependent signaling in primary neurons.
